SHINE was founded in 2010 by Greg Piefer and is a development-stage company working toward becoming the world-leading medical isotope producer.
The SHINE production facility will use a patented, proprietary manufacturing process to produce medical tracers and cancer treatment elements for nuclear medicine. The SHINE technology offers major advantages over existing and proposed production technologies, as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the existing global supply chain for molybdenum-99.